Leerink Partners Maintains Market Perform on 10x Genomics, Raises Price Target to $90

Benzinga Newsdesk www.benzinga.com Positive 62.5%

Neg 0% Neu 0% Pos 62.5%

Leerink Partners analyst Mike Kratky maintains 10x Genomics (NASDAQ:TXG) with a Market Perform and raises the price target from $40 to $90.